Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive versus standard therapy for severe lupus nephritis
ChiCTR-TRC-09000587Phase 4Completed
- Sponsor
- Peking University People's Hospital
- Start
- Oct 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cyclophosphamide, hydroxychloroquine, mycophenolate mofetil, leflunomide, azathioprine and 1 more in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Serum albumin, Serum creatinine and 1 more. Started Oct 2009; status: completed.
02
Drugs
cyclophosphamidehydroxychloroquinemycophenolate mofetilleflunomideazathioprine
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR-TRC-09000587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-09000587.